Company Encyclopedia
View More
name
Aclarion
ACON.US
Aclarion, Inc. operates as a healthcare technology company in the United States. The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. It develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine.
65.89 B
ACON.USMarket value -Rank by Market Cap -/-

Financial Score

26/12/2025 Update
C
Health Care TechnologyIndustry
Industry Ranking29/46
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-98.44%E
    • Profit Margin-10868.01%E
    • Gross Margin23.15%D
  • Growth ScoreA
    • Revenue YoY36.91%A
    • Net Profit YoY-17.63%D
    • Total Assets YoY314.06%A
    • Net Assets YoY398.07%A
  • Cash ScoreB
    • Cash Flow Margin-0.91%D
    • OCF YoY36.91%A
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreA
    • Gearing Ratio5.30%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Aclarion Nociscan Study Published in Leading Spine Surgery Journal

    Aclarion Inc. announced the publication of an article on its Nociscan technology in the International Journal of Spine Surgery. The article highlights a successful clinical case where Nociscan, used with MRI, accurately identified the source of chronic low back pain, leading to targeted surgical intervention and the patient's full recovery. These results strengthen the clinical evidence supporting Nociscan.

    Reuters·
    US
    ACON
    -8.33%
    Reuters·
    US
    ACON
    -8.33%

    Aclarion CEO Brent Ness Reports Acquisition of Common Shares

    Aclarion Inc. CEO Brent Ness reported acquiring common shares of the company. The full filing is available via EDGAR, the U.S. SEC's system. This AI-generated news brief by Public Technologies is for informational purposes only and not financial advice.

    Reuters·
    US
    ACON
    -8.33%
    Reuters·
    US
    ACON
    -8.33%

    Aclarion | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 18.94 K

    LB filings·
    US
    ACON
    -8.33%
    LB filings·
    US
    ACON
    -8.33%

    Aclarion, Inc. SEC 10-Q Report

    Aclarion, Inc. has released its Q3 2023 10-Q report, highlighting significant revenue growth of $18,942, primarily from NOCISCAN® reports in the UK. The gross profit improved to $4,386, while the net loss was $(1,706,294). The company increased sales and marketing expenses due to the Clarity trial and external consultants. Future outlook indicates continued revenue growth and increased R&D expenses as the company expands its insurance payor base and scan volumes. The SEC filing is dated Nov. 12, 2025.

    TradingView·
    US
    ACON
    -8.33%
    TradingView·
    US
    ACON
    -8.33%

    Aclarion Wins "Rising Star" at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

    Aclarion Wins "Rising Star" at 2025 Digital Health Hub Foundation: Digital Health Awards at ...

    GlobeNewswire·
    US
    ACON
    -8.33%
    GlobeNewswire·
    US
    ACON
    -8.33%
    © 2025 Longbridge｜Disclaimer